{"id":"triflupromazine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute disease of cardiovascular system","Alcoholism","Anemia","Angina pectoris","At risk for aspiration","Benign prostatic hyperplasia","Bradycardia","Breastfeeding (mother)","Carcinoma of female breast","Chronic disease of respiratory system","Chronic heart failure","Coma","Conduction disorder of the heart","Congenital long QT syndrome","Disease of liver","Epilepsy","Extrapyramidal disease","Glaucoma","Hyperglycemia","Hyperprolactinemia","Leukopenia","Metabolic syndrome X","Myocardial infarction","Myocardial ischemia","Neuroleptic malignant syndrome","Neutropenic disorder","Obesity","Organophosphate poisoning","Orthostatic hypotension","Parkinsonism","Prolonged QT interval","Retention of urine","Senile dementia","Stupor","Tardive dyskinesia","Thrombocytopenic disorder","Torsades de pointes","Visual impairment","Weight gain finding"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1201102","moleculeType":"Small molecule","molecularWeight":"388.89"},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:21:06.822509","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TRIFLUPROMAZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:55:08.921164+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:55:14.842646+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIFLUPROMAZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:55:15.222196+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dopamine D2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:55:16.350226+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201102/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:55:16.008611+00:00"}},"allNames":"psyquil","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Multidrug resistance protein 1, 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:37:47.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:55:17.580223+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Nausea","diseaseId":"nausea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nausea and vomiting","diseaseId":"nausea-and-vomiting","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psychotic disorder","diseaseId":"psychotic-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vomiting","diseaseId":"vomiting","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1201102"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":280,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Psyquil","genericName":"TRIFLUPROMAZINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1957","aiSummary":"Psyquil is a small molecule that acts as a dopamine D2 receptor antagonist. It is classified as an antagonist and has been known by various synonyms, including Triflupromazine.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:55:17.580223+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}